Sign In
Buy AZRX
$0.155
-0.0080 (-4.90%)
At Close: Aug 17, 2022
Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX)
07:08pm, Friday, 29'th May 2020
In this article you are going to find out whether hedge funds think AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a good investment right now. We like to check what the smart money thinks first before doing
Under the terms of the agreement, Creapharm will package, label, provide qualified person (QP) release and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTIO
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
12:00pm, Tuesday, 05'th May 2020
This marks the third CIR payment AzurRx SAS has received in 2020. Since March including the 2019 CIR, the Company has received approximately $2.52 million in non-dilutive funding in research tax cred
What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)?
10:45am, Monday, 04'th May 2020
Anyone researching AzurRx BioPharma, Inc. (NASDAQ:AZRX) might want to consider the historical volatility of the share...
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the.
On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsulesTrial.
AzurRx BioPharma Issues Letter to Shareholders
12:00pm, Tuesday, 21'st Apr 2020
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the fo
Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc.(NasdaqCM: AZRX)
12:00pm, Monday, 20'th Apr 2020
NEW YORK, April 20, 2020 -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX).
AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product
06:00pm, Thursday, 16'th Apr 2020
Under the terms of the agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibr
AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
12:00pm, Wednesday, 15'th Apr 2020
BROOKLYN, NY / ACCESSWIRE / April 15, 2020 / AzurRx BioPharma, Inc. (NASDAQ:AZRX), is a clinical stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of
AzurRx Appoints Gregory Oakes to its Board of Directors
02:30pm, Thursday, 09'th Apr 2020
“Greg is a strong and welcomed addition to our board,” said James Sapirstein, CEO of AzurRx BioPharma. "I am excited to join the AzurRx Board with its compelling potential synthetic alternative t
Analysts Offer Insights on Healthcare Companies: Sorrento Therapeutics (SRNE) and AzurRx BioPharma (AZRX)
11:22am, Monday, 06'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sorrento Therapeutics (SRNE) and AzurRx BioPharma (AZRX)
Analysts Offer Insights on Healthcare Companies: Sorrento Therapeutics (NASDAQ: SRNE) and AzurRx BioPharma (NASDAQ: AZRX)
11:21am, Monday, 06'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sorrento Therapeutics
AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)
04:00pm, Wednesday, 01'st Apr 2020
In March 2020, the Company announced it had received $1.13 million for its 2018 CIR for an aggregate total of $1.77 million in non-dilutive funding received in 2020. In addition, the Company anticipa
Analyzing Taro Pharmaceutical Industries (NYSE:TARO) & AzurRx BioPharma (NYSE:AZRX)
05:42am, Wednesday, 25'th Mar 2020
AzurRx BioPharma (NASDAQ:AZRX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of th
